Skip to main content


Latest articles

17-05-2019 | Rheumatology | News | Article

More than two infliximab escalations may be unwarranted in RA

The clinical benefit of infliximab dose escalation in people with rheumatoid arthritis may be limited to the initial two escalations, US study findings indicate.

16-05-2019 | Rheumatology | News | Article

Insights given into TNFi treatment patterns for patients with PsA

Patients initiating their first tumor necrosis factor inhibitor for psoriatic arthritis have a longer time to discontinuation and are less likely to switch treatment than those previously treated with a drug from the same class, say researchers.

15-05-2019 | Rheumatology | News | Article

Pooled analysis demonstrates favorable long-term safety profile of secukinumab

Analysis of data from 21 randomized controlled trials indicates that the interleukin-17A inhibitor secukinumab has a favorable long-term safety profile among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis.

14-05-2019 | Rheumatology | News | Article

Individualized tool aids treatment decision-making for women with lupus nephritis

SMILE, an individualized and culturally tailored patient decision aid, has been shown to reduce decisional conflict regarding choice of immunosuppressive treatment in a randomized trial involving a diverse group of women with lupus nephritis.

13-05-2019 | Rheumatology | Highlight | Article

Switch from adalimumab to baricitinib may benefit some RA patients

Analysis of data from the RA-BEAM and RA-BEYOND trials suggests that switching from adalimumab to baricitinib is associated with improvements in disease control and patient-reported outcomes in patients with rheumatoid arthritis, with an acceptable safety profile.

10-05-2019 | Rheumatology | News | Article

Low-load resistance training with blood flow restriction benefits women with RA

Supervised low-load resistance training combined with partial blood flow restriction is as effective as high‐load resistance training in improving muscle strength and function in women with rheumatoid arthritis (RA), study findings indicate.

09-05-2019 | Rheumatology | News | Article

RA patients continue to have excess risk for joint replacement

Approximately one in five people diagnosed with rheumatoid arthritis will need a knee or hip replacement during their remaining lifetime, shows an analysis of data from the UK’s National Health Service.

08-05-2019 | Rheumatology | News | Article

Risk factors for falls after joint replacement described

The authors of a systematic review and meta-analysis have identified several modifiable and nonmodifiable risk factors for falls following hip or knee replacement.

07-05-2019 | Rheumatology | News | Article

ACR/National Arthritis Foundation guidelines for managing JIA released

The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.

03-05-2019 | Rheumatology | News | Article

Meta-analysis supports increased herpes zoster risk with JAK inhibitors

Findings from a systematic review and meta-analysis indicate that the incidence of herpes zoster among rheumatoid arthritis patients treated with Janus kinase inhibitors is higher than expected in this population, and baricitinib is associated with a significantly increased risk.

02-05-2019 | Rheumatology | News | Article

Multifactorial nature of cognitive dysfunction highlighted in SLE

Poor attenuation of the default mode network regions of the brain may contribute to cognitive impairments in patients with systemic lupus erythematosus, say UK researchers.

01-05-2019 | Rheumatology | News | Article

CD40L blockade shows promise for RA

Findings from a proof-of-concept study provide preliminary evidence that the CD40 ligand binding agent VIB4920 may be a promising treatment option for rheumatoid arthritis.

30-04-2019 | Rheumatology | News | Article

Belimumab approved for pediatric lupus in the USA

Click through for more details

29-04-2019 | Rheumatology | News | Article

Home-based rehabilitation ‘appropriate’ after uncomplicated TKR

Clinic-based or inpatient rehabilitation programs are not superior to home-based programs for individuals who undergo total knee replacement without complications, suggests a systematic review and meta-analysis.

29-04-2019 | Rheumatology | News | Article

FDA approves etanercept biosimilar

Click through for more information on this announcement

26-04-2019 | Rheumatology | News | Article

Namilumab shows promise in phase II trial

Namilumab induces a rapid and sustained clinically significant response in patients with moderate-to-severe rheumatoid arthritis, with a favorable tolerability profile, show results of the phase II NEXUS trial.

25-04-2019 | Rheumatology | News | Article

No difference in fracture risk with denosumab vs alendronate

Patients initiating denosumab have a similar 3-year fracture risk to those initiating alendronate, regardless of sex, age, or fracture history, show results of a large study among Danish patients in routine clinical practice.

24-04-2019 | Rheumatology | News | Article

HDL cholesterol levels may predict CV risk in tofacitinib-treated RA patients

Increasing levels of high-density lipoprotein cholesterol are associated with a reduction in cardiovascular risk among rheumatoid arthritis patients undergoing treatment with the Janus kinase inhibitor tofacitinib, researchers report.

24-04-2019 | Rheumatology | News | Article

Long-term drug treatment may reduce fracture risk in women with osteoporosis

Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

23-04-2019 | Rheumatology | News | Article

Reducing tocilizumab frequency may jeopardize remission status in RA

Doubling the dose interval of subcutaneous tocilizumab after 24 weeks reduces the likelihood of maintaining remission without improving tolerability in patients with moderate-to severe rheumatoid arthritis, study findings indicate.

Image Credits